Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2013-08

AUTHORS

A Z Badros, R Vij, T Martin, J A Zonder, L Kunkel, Z Wang, S Lee, A F Wong, R Niesvizky

ABSTRACT

This phase 2 study assessed the safety, pharmacokinetics, pharmacodynamics and efficacy of carfilzomib, a selective proteasome inhibitor, in patients with multiple myeloma and varying degrees of renal impairment, including patients on chronic hemodialysis. Patients were grouped by creatinine clearance: >80 ml/min, 50-80 ml/min, 30-49 ml/min, <30 ml/min and chronic hemodialysis. Carfilzomib was administered on days 1, 2, 8, 9, 15 and 16 in 28-day cycles: 15 mg/m(2) (Cycle 1), 20 mg/m(2) (Cycle 2) and 27 mg/m(2) (Cycles 3+). There were no differences in carfilzomib clearance or exposure among patients with normal renal function and any group with renal impairment. Grade 3/4 adverse events (AEs) included anemia (28.0%), thrombocytopenia (20.0%), lymphopenia (18.0%) and fatigue (14.0%). AEs were similar among groups. At 15 mg/m(2), proteasome inhibition up to 85% was observed and did not differ among groups. Although nearly 50% of patients were refractory to both bortezomib and lenalidomide, end of study partial response or better (overall response rate) was 25.5% with 7.9 months median duration of response. In conclusion, the pharmacokinetics and safety of carfilzomib were not influenced by the degree of baseline renal impairment, including in patients on dialysis, and carfilzomib was well tolerated and demonstrated promising efficacy. More... »

PAGES

1707

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/leu.2013.29

DOI

http://dx.doi.org/10.1038/leu.2013.29

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1023785372

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/23364621


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Function Tests", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Multiple Myeloma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oligopeptides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proteasome Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Renal Insufficiency", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "M and S Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Badros", 
        "givenName": "A Z", 
        "id": "sg:person.01352622437.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01352622437.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Washington University in St. Louis", 
          "id": "https://www.grid.ac/institutes/grid.4367.6", 
          "name": [
            "Washington University School of Medicine, St Louis, MO, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vij", 
        "givenName": "R", 
        "id": "sg:person.01163517522.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01163517522.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of California, San Francisco", 
          "id": "https://www.grid.ac/institutes/grid.266102.1", 
          "name": [
            "The University of California, San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Martin", 
        "givenName": "T", 
        "id": "sg:person.01064755051.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01064755051.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Wayne State University", 
          "id": "https://www.grid.ac/institutes/grid.254444.7", 
          "name": [
            "Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zonder", 
        "givenName": "J A", 
        "id": "sg:person.0667071771.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0667071771.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Independent Consultant, San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kunkel", 
        "givenName": "L", 
        "id": "sg:person.01106404207.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01106404207.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Onyx Pharmaceuticals, Inc., South San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wang", 
        "givenName": "Z", 
        "id": "sg:person.01153747066.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01153747066.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Onyx Pharmaceuticals, Inc., South San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lee", 
        "givenName": "S", 
        "id": "sg:person.01050304516.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01050304516.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Onyx Pharmaceuticals, Inc., South San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wong", 
        "givenName": "A F", 
        "id": "sg:person.015702763512.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015702763512.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cornell University", 
          "id": "https://www.grid.ac/institutes/grid.5386.8", 
          "name": [
            "Weill Cornell Medical College, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Niesvizky", 
        "givenName": "R", 
        "id": "sg:person.0736002261.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0736002261.25"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.4065/78.1.21", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003030843"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2141.2009.07803.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003568562"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2141.2009.07803.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003568562"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1034/j.1600-0609.2000.90221.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004546078"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2012.182", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006680313", 
          "https://doi.org/10.1038/leu.2012.182"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/dmd.111.039164", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007009347"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2010.30.8791", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010368281"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-09-0822", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010603266"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2012-05-425934", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011406947"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2008-04-149385", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021021356"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-11-3007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026589995"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-11-3007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026589995"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-10-1950", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027164449"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2006-09-046409", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027361439"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.leu.2404284", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033553106", 
          "https://doi.org/10.1038/sj.leu.2404284"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.leu.2404284", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033553106", 
          "https://doi.org/10.1038/sj.leu.2404284"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2012-04-422683", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035718204"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3324/haematol.2011.049767", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036939343"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2012-03-414359", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040165478"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1600-0609.1994.tb00190.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046564957"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1600-0609.1994.tb00190.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046564957"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2141.2012.09232.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047125405"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/archinte.158.17.1889", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048714833"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1365-2141.1998.00930.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051933965"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1089/blr.2006.25.447", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059238419"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077852517", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2010.28.15_suppl.8147", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083944521"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2013-08", 
    "datePublishedReg": "2013-08-01", 
    "description": "This phase 2 study assessed the safety, pharmacokinetics, pharmacodynamics and efficacy of carfilzomib, a selective proteasome inhibitor, in patients with multiple myeloma and varying degrees of renal impairment, including patients on chronic hemodialysis. Patients were grouped by creatinine clearance: >80\u2009ml/min, 50-80\u2009ml/min, 30-49\u2009ml/min, <30\u2009ml/min and chronic hemodialysis. Carfilzomib was administered on days 1, 2, 8, 9, 15 and 16 in 28-day cycles: 15\u2009mg/m(2) (Cycle 1), 20\u2009mg/m(2) (Cycle 2) and 27 mg/m(2) (Cycles 3+). There were no differences in carfilzomib clearance or exposure among patients with normal renal function and any group with renal impairment. Grade 3/4 adverse events (AEs) included anemia (28.0%), thrombocytopenia (20.0%), lymphopenia (18.0%) and fatigue (14.0%). AEs were similar among groups. At 15\u2009mg/m(2), proteasome inhibition up to 85% was observed and did not differ among groups. Although nearly 50% of patients were refractory to both bortezomib and lenalidomide, end of study partial response or better (overall response rate) was 25.5% with 7.9 months median duration of response. In conclusion, the pharmacokinetics and safety of carfilzomib were not influenced by the degree of baseline renal impairment, including in patients on dialysis, and carfilzomib was well tolerated and demonstrated promising efficacy.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1038/leu.2013.29", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1097065", 
        "issn": [
          "0887-6924", 
          "1476-5551"
        ], 
        "name": "Leukemia", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "8", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "27"
      }
    ], 
    "name": "Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety", 
    "pagination": "1707", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "71518d3a1d422130e46299f7ee2a46b3e43159f5a647782398587bec6496cd8f"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "23364621"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8704895"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/leu.2013.29"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1023785372"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/leu.2013.29", 
      "https://app.dimensions.ai/details/publication/pub.1023785372"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T17:20", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8672_00000435.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://www.nature.com/articles/leu201329"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/leu.2013.29'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/leu.2013.29'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/leu.2013.29'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/leu.2013.29'


 

This table displays all metadata directly associated to this object as RDF triples.

263 TRIPLES      21 PREDICATES      65 URIs      34 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/leu.2013.29 schema:about N1cc4c1f940f244a5b42442472e71893c
2 N1cecbc7f382243a3b6dd574c1f3aeefd
3 N687f8e055f8e44b79b3ba17288663121
4 N6afcd0b467e0452bbe1baf1c5fadd388
5 N9108ceb49076494eae76b1352d4b0df5
6 N9dd84be825f645ceb658ebeb567a4bd0
7 Nb03ce802297345b1ae86b9fec55c8ea8
8 Nd36226671a6d4ad1905d14b5c4e56431
9 Ne9f7d6a265af4b20a2672a9a03a25fbc
10 Nf29d034078a84dfd8e508119e288dc78
11 Nf7220cc8c6da4003baf86414f8595f8b
12 Nfb540bf06dd24d588be144f505891208
13 Nfcacef51c468467f935c378530851a88
14 anzsrc-for:11
15 anzsrc-for:1103
16 schema:author N4bd4369c3ccd45c9874412c07b1a7e0f
17 schema:citation sg:pub.10.1038/leu.2012.182
18 sg:pub.10.1038/sj.leu.2404284
19 https://app.dimensions.ai/details/publication/pub.1077852517
20 https://doi.org/10.1001/archinte.158.17.1889
21 https://doi.org/10.1034/j.1600-0609.2000.90221.x
22 https://doi.org/10.1046/j.1365-2141.1998.00930.x
23 https://doi.org/10.1089/blr.2006.25.447
24 https://doi.org/10.1111/j.1365-2141.2009.07803.x
25 https://doi.org/10.1111/j.1365-2141.2012.09232.x
26 https://doi.org/10.1111/j.1600-0609.1994.tb00190.x
27 https://doi.org/10.1124/dmd.111.039164
28 https://doi.org/10.1158/1078-0432.ccr-09-0822
29 https://doi.org/10.1158/1078-0432.ccr-10-1950
30 https://doi.org/10.1158/1078-0432.ccr-11-3007
31 https://doi.org/10.1182/blood-2006-09-046409
32 https://doi.org/10.1182/blood-2008-04-149385
33 https://doi.org/10.1182/blood-2012-03-414359
34 https://doi.org/10.1182/blood-2012-04-422683
35 https://doi.org/10.1182/blood-2012-05-425934
36 https://doi.org/10.1200/jco.2010.28.15_suppl.8147
37 https://doi.org/10.1200/jco.2010.30.8791
38 https://doi.org/10.3324/haematol.2011.049767
39 https://doi.org/10.4065/78.1.21
40 schema:datePublished 2013-08
41 schema:datePublishedReg 2013-08-01
42 schema:description This phase 2 study assessed the safety, pharmacokinetics, pharmacodynamics and efficacy of carfilzomib, a selective proteasome inhibitor, in patients with multiple myeloma and varying degrees of renal impairment, including patients on chronic hemodialysis. Patients were grouped by creatinine clearance: >80 ml/min, 50-80 ml/min, 30-49 ml/min, <30 ml/min and chronic hemodialysis. Carfilzomib was administered on days 1, 2, 8, 9, 15 and 16 in 28-day cycles: 15 mg/m(2) (Cycle 1), 20 mg/m(2) (Cycle 2) and 27 mg/m(2) (Cycles 3+). There were no differences in carfilzomib clearance or exposure among patients with normal renal function and any group with renal impairment. Grade 3/4 adverse events (AEs) included anemia (28.0%), thrombocytopenia (20.0%), lymphopenia (18.0%) and fatigue (14.0%). AEs were similar among groups. At 15 mg/m(2), proteasome inhibition up to 85% was observed and did not differ among groups. Although nearly 50% of patients were refractory to both bortezomib and lenalidomide, end of study partial response or better (overall response rate) was 25.5% with 7.9 months median duration of response. In conclusion, the pharmacokinetics and safety of carfilzomib were not influenced by the degree of baseline renal impairment, including in patients on dialysis, and carfilzomib was well tolerated and demonstrated promising efficacy.
43 schema:genre research_article
44 schema:inLanguage en
45 schema:isAccessibleForFree true
46 schema:isPartOf Nc2824c89ada6450a92084a7e43c05fcc
47 Nd85a08e59ddb47ed92bd9997fc8f2ca4
48 sg:journal.1097065
49 schema:name Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety
50 schema:pagination 1707
51 schema:productId N006843e8c88e45e796635cd0f9a579f9
52 N1b870a6383e744e79148c75e9c01199a
53 N720072d361484d2db209e14a18bfc775
54 N99feefb8d3074713843cc2724277922e
55 Na4a45ad874aa408b8162ef3e5a66a8a5
56 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023785372
57 https://doi.org/10.1038/leu.2013.29
58 schema:sdDatePublished 2019-04-10T17:20
59 schema:sdLicense https://scigraph.springernature.com/explorer/license/
60 schema:sdPublisher Nd4c5229c106d4a9da2e3ab7e8e048baa
61 schema:url https://www.nature.com/articles/leu201329
62 sgo:license sg:explorer/license/
63 sgo:sdDataset articles
64 rdf:type schema:ScholarlyArticle
65 N006843e8c88e45e796635cd0f9a579f9 schema:name dimensions_id
66 schema:value pub.1023785372
67 rdf:type schema:PropertyValue
68 N1b870a6383e744e79148c75e9c01199a schema:name readcube_id
69 schema:value 71518d3a1d422130e46299f7ee2a46b3e43159f5a647782398587bec6496cd8f
70 rdf:type schema:PropertyValue
71 N1cc4c1f940f244a5b42442472e71893c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
72 schema:name Middle Aged
73 rdf:type schema:DefinedTerm
74 N1cecbc7f382243a3b6dd574c1f3aeefd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Renal Insufficiency
76 rdf:type schema:DefinedTerm
77 N498a1edce008431eac1e00d165b9d3bc rdf:first sg:person.01050304516.53
78 rdf:rest N7bfb21569ba24829b2ad3268b5dc6a04
79 N4ac8a96df9a44c72a515d1292ac81b47 rdf:first sg:person.0736002261.25
80 rdf:rest rdf:nil
81 N4bd4369c3ccd45c9874412c07b1a7e0f rdf:first sg:person.01352622437.39
82 rdf:rest N9634f8e1fd924490ae3da399de4eefc7
83 N4f2905bea74f459481331dee8e402555 schema:name Independent Consultant, San Francisco, CA, USA
84 rdf:type schema:Organization
85 N687f8e055f8e44b79b3ba17288663121 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Kidney Function Tests
87 rdf:type schema:DefinedTerm
88 N6afcd0b467e0452bbe1baf1c5fadd388 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Aged
90 rdf:type schema:DefinedTerm
91 N720072d361484d2db209e14a18bfc775 schema:name nlm_unique_id
92 schema:value 8704895
93 rdf:type schema:PropertyValue
94 N7bfb21569ba24829b2ad3268b5dc6a04 rdf:first sg:person.015702763512.16
95 rdf:rest N4ac8a96df9a44c72a515d1292ac81b47
96 N81e8f1a41dec460485f102f93a6b2c34 schema:name M and S Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA
97 rdf:type schema:Organization
98 N9108ceb49076494eae76b1352d4b0df5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Treatment Outcome
100 rdf:type schema:DefinedTerm
101 N9634f8e1fd924490ae3da399de4eefc7 rdf:first sg:person.01163517522.72
102 rdf:rest Nc1763768d7df4bc0b84f2fd78863db4c
103 N99feefb8d3074713843cc2724277922e schema:name doi
104 schema:value 10.1038/leu.2013.29
105 rdf:type schema:PropertyValue
106 N9dd84be825f645ceb658ebeb567a4bd0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Multiple Myeloma
108 rdf:type schema:DefinedTerm
109 Na4a45ad874aa408b8162ef3e5a66a8a5 schema:name pubmed_id
110 schema:value 23364621
111 rdf:type schema:PropertyValue
112 Na6392192cb904854b08129dd865616da rdf:first sg:person.0667071771.30
113 rdf:rest Ncc04fc8dd85648b58a5e42003405849f
114 Nb03ce802297345b1ae86b9fec55c8ea8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Aged, 80 and over
116 rdf:type schema:DefinedTerm
117 Nc1763768d7df4bc0b84f2fd78863db4c rdf:first sg:person.01064755051.50
118 rdf:rest Na6392192cb904854b08129dd865616da
119 Nc2824c89ada6450a92084a7e43c05fcc schema:volumeNumber 27
120 rdf:type schema:PublicationVolume
121 Ncc04fc8dd85648b58a5e42003405849f rdf:first sg:person.01106404207.30
122 rdf:rest Nda918ff62de449478986a18493d9734a
123 Nd36226671a6d4ad1905d14b5c4e56431 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Proteasome Inhibitors
125 rdf:type schema:DefinedTerm
126 Nd4c5229c106d4a9da2e3ab7e8e048baa schema:name Springer Nature - SN SciGraph project
127 rdf:type schema:Organization
128 Nd85a08e59ddb47ed92bd9997fc8f2ca4 schema:issueNumber 8
129 rdf:type schema:PublicationIssue
130 Nda918ff62de449478986a18493d9734a rdf:first sg:person.01153747066.24
131 rdf:rest N498a1edce008431eac1e00d165b9d3bc
132 Ne9f7d6a265af4b20a2672a9a03a25fbc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Male
134 rdf:type schema:DefinedTerm
135 Nf29d034078a84dfd8e508119e288dc78 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Antineoplastic Agents
137 rdf:type schema:DefinedTerm
138 Nf7220cc8c6da4003baf86414f8595f8b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Oligopeptides
140 rdf:type schema:DefinedTerm
141 Nfb540bf06dd24d588be144f505891208 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Humans
143 rdf:type schema:DefinedTerm
144 Nfcacef51c468467f935c378530851a88 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Female
146 rdf:type schema:DefinedTerm
147 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
148 schema:name Medical and Health Sciences
149 rdf:type schema:DefinedTerm
150 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
151 schema:name Clinical Sciences
152 rdf:type schema:DefinedTerm
153 sg:journal.1097065 schema:issn 0887-6924
154 1476-5551
155 schema:name Leukemia
156 rdf:type schema:Periodical
157 sg:person.01050304516.53 schema:affiliation https://www.grid.ac/institutes/grid.417886.4
158 schema:familyName Lee
159 schema:givenName S
160 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01050304516.53
161 rdf:type schema:Person
162 sg:person.01064755051.50 schema:affiliation https://www.grid.ac/institutes/grid.266102.1
163 schema:familyName Martin
164 schema:givenName T
165 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01064755051.50
166 rdf:type schema:Person
167 sg:person.01106404207.30 schema:affiliation N4f2905bea74f459481331dee8e402555
168 schema:familyName Kunkel
169 schema:givenName L
170 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01106404207.30
171 rdf:type schema:Person
172 sg:person.01153747066.24 schema:affiliation https://www.grid.ac/institutes/grid.417886.4
173 schema:familyName Wang
174 schema:givenName Z
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01153747066.24
176 rdf:type schema:Person
177 sg:person.01163517522.72 schema:affiliation https://www.grid.ac/institutes/grid.4367.6
178 schema:familyName Vij
179 schema:givenName R
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01163517522.72
181 rdf:type schema:Person
182 sg:person.01352622437.39 schema:affiliation N81e8f1a41dec460485f102f93a6b2c34
183 schema:familyName Badros
184 schema:givenName A Z
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01352622437.39
186 rdf:type schema:Person
187 sg:person.015702763512.16 schema:affiliation https://www.grid.ac/institutes/grid.417886.4
188 schema:familyName Wong
189 schema:givenName A F
190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015702763512.16
191 rdf:type schema:Person
192 sg:person.0667071771.30 schema:affiliation https://www.grid.ac/institutes/grid.254444.7
193 schema:familyName Zonder
194 schema:givenName J A
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0667071771.30
196 rdf:type schema:Person
197 sg:person.0736002261.25 schema:affiliation https://www.grid.ac/institutes/grid.5386.8
198 schema:familyName Niesvizky
199 schema:givenName R
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0736002261.25
201 rdf:type schema:Person
202 sg:pub.10.1038/leu.2012.182 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006680313
203 https://doi.org/10.1038/leu.2012.182
204 rdf:type schema:CreativeWork
205 sg:pub.10.1038/sj.leu.2404284 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033553106
206 https://doi.org/10.1038/sj.leu.2404284
207 rdf:type schema:CreativeWork
208 https://app.dimensions.ai/details/publication/pub.1077852517 schema:CreativeWork
209 https://doi.org/10.1001/archinte.158.17.1889 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048714833
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1034/j.1600-0609.2000.90221.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1004546078
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1046/j.1365-2141.1998.00930.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1051933965
214 rdf:type schema:CreativeWork
215 https://doi.org/10.1089/blr.2006.25.447 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059238419
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1111/j.1365-2141.2009.07803.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1003568562
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1111/j.1365-2141.2012.09232.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1047125405
220 rdf:type schema:CreativeWork
221 https://doi.org/10.1111/j.1600-0609.1994.tb00190.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1046564957
222 rdf:type schema:CreativeWork
223 https://doi.org/10.1124/dmd.111.039164 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007009347
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1158/1078-0432.ccr-09-0822 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010603266
226 rdf:type schema:CreativeWork
227 https://doi.org/10.1158/1078-0432.ccr-10-1950 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027164449
228 rdf:type schema:CreativeWork
229 https://doi.org/10.1158/1078-0432.ccr-11-3007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026589995
230 rdf:type schema:CreativeWork
231 https://doi.org/10.1182/blood-2006-09-046409 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027361439
232 rdf:type schema:CreativeWork
233 https://doi.org/10.1182/blood-2008-04-149385 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021021356
234 rdf:type schema:CreativeWork
235 https://doi.org/10.1182/blood-2012-03-414359 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040165478
236 rdf:type schema:CreativeWork
237 https://doi.org/10.1182/blood-2012-04-422683 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035718204
238 rdf:type schema:CreativeWork
239 https://doi.org/10.1182/blood-2012-05-425934 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011406947
240 rdf:type schema:CreativeWork
241 https://doi.org/10.1200/jco.2010.28.15_suppl.8147 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083944521
242 rdf:type schema:CreativeWork
243 https://doi.org/10.1200/jco.2010.30.8791 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010368281
244 rdf:type schema:CreativeWork
245 https://doi.org/10.3324/haematol.2011.049767 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036939343
246 rdf:type schema:CreativeWork
247 https://doi.org/10.4065/78.1.21 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003030843
248 rdf:type schema:CreativeWork
249 https://www.grid.ac/institutes/grid.254444.7 schema:alternateName Wayne State University
250 schema:name Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
251 rdf:type schema:Organization
252 https://www.grid.ac/institutes/grid.266102.1 schema:alternateName University of California, San Francisco
253 schema:name The University of California, San Francisco, CA, USA
254 rdf:type schema:Organization
255 https://www.grid.ac/institutes/grid.417886.4 schema:alternateName Amgen (United States)
256 schema:name Onyx Pharmaceuticals, Inc., South San Francisco, CA, USA
257 rdf:type schema:Organization
258 https://www.grid.ac/institutes/grid.4367.6 schema:alternateName Washington University in St. Louis
259 schema:name Washington University School of Medicine, St Louis, MO, USA
260 rdf:type schema:Organization
261 https://www.grid.ac/institutes/grid.5386.8 schema:alternateName Cornell University
262 schema:name Weill Cornell Medical College, New York, NY, USA
263 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...